Tag
This article examines interleukin-6 (IL-6) as a key mediator of therapeutic efficacy in acute lung injury and COVID-19, highlighting its role in modulating inflammation and survival outcomes across multiple clinical interventions.
Systemic IL-6 inhibitors are linked to significantly reduced risks of diabetic retinopathy development, progression, and vision-threatening complications, suggesting therapeutic potential for diabetic eye disease.
Higher blood IL-6 levels were strongly linked to nine cardiovascular and mortality outcomes in nearly 60,000 adults, supporting IL-6 as an important inflammatory marker and potential prevention target.
A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, th
A pooled analysis of 59,396 participants found that higher serum IL-6 concentrations independently predicted nine cardiovascular and mortality outcomes, with consistent associations across key clinical subgroups.
In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
